🔗 Share this article Social Media Influencers Fueling Parallel Market for Unlicensed Slimming Medication A shadow economy for unapproved slimming drugs is being driven by social media fitness personalities and vendors on communication apps, according to recent findings. Investigational Drug Acquiring Traction Online Retatrutide, which remains in clinical trials, is being advertised by social media influencers for its supposed weight-reducing effects. Followers are urged to contact these profiles directly for supplier links, while also receiving discount codes. Active Commerce on Messaging Platforms Separately, a robust market exists on messaging services, where communities with thousands of members share comparison images, administration instructions and claims of next-day UK delivery. Vendors promote the substance there before redirecting buyers to WhatsApp for purchases. Learning About The Experimental Drug This medication is an experimental injectable created by US drugmaker Eli Lilly. The drug affects three intestinal hormones – glucagon-like peptide-1, GIP and glucagon. Early trials suggest it could help patients reduce up to a quarter of their body weight. Nicknamed the “triple G”, the substance is being hailed digitally as the successor to Ozempic. Medical Professionals Voice Concerns Nevertheless, physicians and pharmacists have cautions that the sale of what is still an unlicensed drug in the UK is worrisome and could lead to users injecting substances of uncertain source. Several professionals said the popularity for the experimental drug could be linked to the increasing cost of licensed slimming treatments such as Mounjaro. Legal Position and Enforcement Marketing retatrutide on social media or messaging apps is prohibited in the United Kingdom, as it is an unapproved drug that must not be promoted or supplied for human use under the Human Medicines Regulations 2012. Several influencers try to circumvent the rules by calling to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted drug, but advertising and distribution can still breach pharmaceutical, marketing, and customer regulations, risking fines, prosecution or prison. Service Reaction and Material Elimination Based on TikTok, the service has taken down problematic content and prohibited related hashtags and search suggestions. The company stated it was committed to keeping the service secure and allocating resources in enhancing enforcement strategies. Digital Marketplace Activities Research also found groups with up to nine thousand participants marketing the experimental drug using the platform's integrated discovery tool, which operates like a public directory. Entering “retatrutide” instantly displays groups with numerous of users, filled with images of weight loss, positive testimonials and detailed guides for preparing or administering at home. Within minutes of entering one community, a seller shared contact information, where most purchases take place. The seller sent an instruction manual and promised shipping within two days. When asked whether the product was genuine, one vendor responded: “You can’t be sure.” Another shared a image of a alleged laboratory certificate. None asked about body mass, medical conditions or past usage. Product Details and Costs Within these groups, posts show dark colored packages with postal service stickers, stating to contain new batches. One communication read: “It took eight of us to load them this morning.” Buyers can select between dry substance containers, prepared at home with purified liquid, or ready-to-use injectors typically priced at £160 for 20mg. When asked how much time a injector should be used, vendors give conflicting answers ranging from a few weeks to “depends on your body”. Service Oversight and Safety Actions A spokesperson for the messaging service stated it regularly moderated harmful material on its service including material that encouraged the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”. Medical Professional Warnings “Individuals are administering substances they cannot confirm. Even if the science behind retatrutide is sound, these online versions may not contain what they advertise,” stated a pharmacy expert, the head of pharmaceutical services at a pharmacy service. Dr Crystal Wyllie of an online medical service connected the increase in demand to current price rises for authorized slimming drugs such as Mounjaro. “With costs rising, individuals are using online platforms. But counterfeit treatments are extremely risky. You can’t be certain what’s contained or whether the environment they were produced in was clean,” she said. Her staff has already seen individuals injured by personal administration from unverified sources. “We recognize the disappointment, but purchasing from Telegram or WhatsApp is gambling with your health,” stated the doctor. “These materials could be impure or incorrectly dosed.” Producer Position A representative from Eli Lilly stated retatrutide was in third stage clinical trials and had not been reviewed or authorized by any regulatory agency anywhere in the world. “Consequently at this time no one can sell [it] for personal consumption,” they explained, noting that any item “falsely representing itself as a company investigational substance not yet approved … may subject users to potentially serious medical dangers”.